CoChat
Sign Up
Cited by 32Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchNeuroinflammation and Neurodegeneration Mechanisms

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Variable Deposition of Amyloid β-Protein (Aβ) with the Carboxy-Terminus that Ends at Residue Valine40 (Aβ40) in the Cerebral Cortex of Patients with Alzheimer's Disease: A Double-Labeling Immunohistochemical Study with Antibodies Specific for Aβ40 and the Aβ that Ends at Residues Alanine42/Threonine43 (Aβ42)

Akiyama, Haruhiko, Mori, Hiroshi, Sahara, Naruhiko, Kondo, Hiromi, Ikeda, Kenji, Nishimura, Toru, Oda, Tatsuro, McGeer, Patrick L.·1997·Neurochemical Research
DOI 10.1023/a:1021910729963
Open this paper in CoChat — free account

Abstract

Amyloid beta-protein (A beta) deposits in the cerebral cortices of patients with Alzheimer's disease (AD) were investigated immunohistochemically to determine their carboxy terminal sequences. Antibodies specific for A beta terminating at residue valine40 (A beta 40) and at residues alanine42/threonine43 (A beta 42) were used. Virtually all parenchymal A beta deposits were positive for A beta 42. Many of these deposits were also partially or completely labeled for A beta 40. The degree of A beta 40 labeling varied from area to area within a given brain and from AD case to AD case. In contrast to parenchymal deposits, A beta 40 labeled essentially all the vascular deposits which constitute amyloid angiopathy (AA), with A beta 42 occurring variably in some of these deposits. Occasional AA was found, however, in which A beta 42 predominated or was exclusively deposited. Such a diversity of A beta species, both in brain parenchyma and in AA, suggests that multiple C-terminal processing mechanisms occur in the cell types responsible for these deposits.

Overview

Integrity signals

Registry

Crossref · 10.1023/a:1021910729963

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 22

  1. Selkoe, D. J. 1994. Normal and abnormal biology of the β-amyloid precursor protein. Annu. Rev. Neurosci. 17:489–517. · DOI
  2. Mori, H., Takio, K., Ogawara, M., and Selkoe, D. J. 1992. Mass spectrometry of purified amyloid β protein in Alzheimer's disease. J. Biol. Chem. 267:17082–17086. · DOI
  3. Roher, A. E., Lowenson, J. D., Clarke, S., Woods, A. S., Cotter, R. J., Gowing, E., and Ball, M. J. 1993. β-Amyloid–(1–42) is a major component of cerebrovascular amyloid deposits: Implications for the pathology of Alzheimer disease. Proc. Natl. Acad. Sci. USA 90:10836–10840. · DOI · Paper page
  4. Näslund, J., Schierhorn, A., Hellman, U., Lannfelt, L., and Roses, A. D. 1994. Relative abundance of Alzheimer Aβ amyloid peptide variants in Alzheimer disease and normal aging. Proc. Natl. Acad. Sci. USA 91:8378–8382. · DOI · Paper page
  5. Greenberg, B. D. 1995. The COOH-terminus of the Alzheimer amyloid Aβ peptide: differences in length influence the process of amyloid deposition in Alzheimer brain, and tell us something about relationships among parents. Amyloid: Int. J. Exp. Clin. Invest. 2:195–203. · DOI
  6. Iwatsubo, T., Mann, D. M. A., Odaka, A., Suzuki, N., Ihara, Y. 1995. Amyloid β protein (Aβ) deposition: Aβ42(43) precedes Aβ40 in Down syndrome. Ann. Neurol. 37:294–299. · DOI
  7. Savage, M. J., Kawooya, J. K., Pinsker, L. R., Emmons, T. L., Mistretta, S., Siman, R., and Greenberg, B. D. 1995. Elevated Aβ levels in Alzheimer's disease brain are associated with selective accumulation of Aβ(42) in parenchymal amyloid plaques and both Aβ(40) and Aβ(42) in cerebrovascular deposits. Amyloid: Int. J. Exp. Clin. Invest. 2:234–240. · DOI
  8. Tamaoka, A., Sawamura, N., Odaka, A., Suzuki, N., Mizusawa, H., Shoji, S., and Mori, H. 1995. Amyloid β-protein 1–42/43 (Aβ1–42/43) in cerebellar diffuse plaques: enzyme-linked immunosorbent assay and immunocytochemical study. Brain Res. 679:151–156. · DOI
  9. Yamaguchi, H., Sugihara, S., Ishiguro, K., Takashima, A., and Hirai, S. 1995. Immunohistochemical analysis of COOH-termini of amyloid β protein (Aβ) using end-specific antisera for Aβ40 and Aβ42 in Alzheimer's disease and normal aging. Amyloid: Int. J. Exp. Clin. Invest. 2:7–16. · DOI
  10. Gearing, M., Schneider, J. A., Robbins, R. S., Hollister, R. D., Mori, H., Games, D., Hyman, B. T., and Mirra, S. S. 1995. Regional variation in the distribution of apolipoprotein E and Aβ in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 54:833–841. · DOI
  11. Gearing, M., Tigges, J., Mori, H., and Mirra, S. S. 1997. Aβ40 is a major form of β-amyloid in nonhuman primates. Neurobiol of Aging (in press). · DOI
  12. Yamaguchi, H., Nakazato, Y., Shoji, M., Okamoto, K., Iahara, Y., and Hirai, S. 1991. Secondary deposition of β-amyloid within extracellular neurofibrillary tangles in Alzheimer-type dementia. Am. J. Pathol. 138:699–705.
  13. Schwab, C., Steele, J. C., Akiyama, H., and McGeer, P. L. 1996. Distinct distribution of apolipoprotein E and beta-amyloid immunoreactivity in the hippocampus of parkinson dementia complex of Guam. Acta Neuropathol. 92:378–385. · DOI
  14. Fukumoto, H., Asami-Okada, A., Suzuki, N., Shimada, H., Ihara, Y., and Iwatsubo, T. 1996. Amyloid β-protein deposition in normal aging has the same characteristics as that in Alzheimer's disease. Am. J. Pathol. 148:259–265.
  15. Jarrett, J. T., Berger, E. P., and Lansbury, Jr. P. T. 1993. The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochem. 32:4693–4697. · DOI · Paper page
  16. Jarrett, J. T., and Lansbury, Jr. P. T. 1993. Seeding “one-dimensional crystallization” of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73:1055–1058. · DOI · Paper page
  17. Maggio, J. E., Stimson, E. R., Ghilardi, J. R., Allen, C. J., Dahl, C. E., Whitcomb, D. C., Vigna, S. R., Vinters, H. V., Labenski, M. E., and Mantyg, P. W. 1992. Reversible in vitro growth of Alzheimer disease β-amyloid plaques by deposition of labeled amyloid peptide. Proc. Natl. Acad. Sci. USA 89: 5462–5466. · DOI
  18. Prior, R., D'Urso, D., Frank, R., Prikulis, I., Cleven, S., Ihl, R., and Pavlakovic, G. 1996. Selective binding of soluble Aβ1–40 and Aβ1–42 to a subset of senile plaques. Am. J. Pathol. 148:1749–1756.
  19. Gowing, E. Roher, A. E., Woods, A. S., Cotter, R. J., Chaney, M., and Little, S. P. 1994. Chemical characterization of Aβ 17–42 peptide, a component of diffuse amyloid deposits of Alzheimer disease. J. Biol. Chem. 269:10987–10990. · DOI · Paper page
  20. Perry, G., Cras, P., Siedlak, S. L., Tabaton, M., and Kawai, M. 1992. β-Protein immunoreactivity is found in the majority of neurofibrillary tangles of Alzheimer's disease. Am. J. Pathol. 140: 283–290.
  21. Cummings, B. J., Satou, T., Head, E., Milgram, N. W., Cole, G. M., Savage, M. J., Podlisny, M. B., Selkoe, D. J., Siman, R., Greenberg, B. D., and Cotman, C. W. 1996. Diffuse plaques contain C-terminal Aβ42 and not Aβ40: Evidence from cats and dogs. Neurobiol. Aging 17:653–659.
  22. Giaccone, G., Pedrotti, B., Migheli, A., Verga, L., Perez, J., Racagni, G., Smith, M. A., Perry, G., De Gioia, L., Selvaggini, C., Salmona, M., Ghiso, J., Frangione, B., Islam, K., Bugiani, O., and Tagliavini, F. 1996. βAPP and tau interaction. A possible link between amyloid and neurofibrillary tangles in Alzheimer's disease. Am. J. Pathol. 148:79–87.

Cited by

Sorted by citations

Metadata

Authors
Akiyama, H., Mori, H., Sahara, N., Kondo, H., Ikeda, K., Nishimura, T., Oda, T., & McGeer, P. L.
Affiliations
  • Tokyo Institute of Psychiatry (JP)
  • University of British Columbia (CA)
Corresponding author
Akiyama, Haruhiko
ORCID
Venue
Neurochemical Research
Publisher
Springer Science and Business Media LLC
Published
1997-12
Volume
22
Issue
12
Pages
1499-1506
ISSN
  • 0364-3190 (ISSN-L)
  • 1573-6903
DOI
10.1023/a:1021910729963
OpenAlex
W1513148410
Cited by
32
References
4
Citations by year
2026: 1 · 2024: 1 · 2022: 2 · 2021: 2 · 2020: 4 · 2017: 3 · 2016: 2 · 2014: 1 · 2013: 1
FWCI
1.41
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Neurochemical Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
Keywords
amyloid-beta, Aβ40, amyloid-beta 42, Alzheimer's disease, cerebral cortex, amyloid angiopathy, amyloid deposits, vascular amyloid deposits, antibody specificity
MeSH terms
Aged, Aged, 80 and over, Alanine, Alzheimer Disease, Antibodies, Antibody Specificity, Cerebral Cortex, Female, Humans, Immunohistochemistry, Male, Peptide Fragments, Staining and Labeling, Threonine, Valine, Amyloid beta-Peptides, Neurofibrillary Tangles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review